查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2010061

消化器官系统药物市场：2026-2032年全球市场预测（依药物类别、给药途径、分子类型、剂型、适应症、最终用户和分销管道划分）

Gastrointestinal Drugs Market by Drug Class, Route Of Administration, Molecule Type, Formulation Type, Indication, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025年，胃肠道药物市场价值为622.3亿美元，预计到2026年将成长至654.5亿美元，复合年增长率为5.45%，到2032年将达到902.6亿美元。

主要市场统计数据
基准年 2025 622.3亿美元
预计年份：2026年 654.5亿美元
预测年份 2032 902.6亿美元
复合年增长率 (%) 5.45%

对不断发展的胃肠道治疗生态系统进行策略性展望，概述临床因素、医疗保健服务的变革、法规环境的变化以及以患者为中心的创新。

胃肠道治疗市场正处于转折点，其驱动因素包括临床因素、人口因素和技术因素。儘管慢性胃肠道疾病和急性症状的治疗仍然是产品需求的主要驱动力，但不断发展的治疗标准和患者期望正迫使製药公司在作用机制、製剂和给药方法方面进行创新。标靶小分子化合物、生物製药支持策略以及以微生物组为中心的疗法等新治疗方法正在重新定义治疗模式，并为临床差异化开闢新的途径。

重大的科学、监管和商业性变革正在透过微生物组科学、精准医疗和数位化医疗服务重塑胃肠道护理。

近年来，胃肠道疾病的认知、治疗和管理方式发生了翻天覆地的变化。科学进步不再局限于缓解症状，而是转向干预潜在的病理生理机制，例如标靶药物以影响胃酸分泌、肠道蠕动和黏膜发炎。同样重要的是，微生物组科学作为一种潜在的治疗方式正在崛起。调节微生物组和肠道屏障功能的干预措施正从发现阶段进入临床试验，这对传统的药物研发路径提出了新的挑战。

贸易政策和关税措施的变化如何重塑消化器官系统药物的供应链选择、成本结构、筹资策略和市场定位。

关税和贸易措施的推出可能会显着改变消化器官系统药品生产商和经销商的成本结构、供应链设计和采购决策。进口活性药物原料药和成品的关税提高会立即对投入成本造成压力，迫使企业重新评估与供应商的关係、合约条款和库存策略。为了因应这种情况，企业通常会寻求生产近岸外包、扩大双重采购策略，并加强与合约开发和生产合作伙伴的合作，以维持获利能力和供应的连续性。

将治疗领域、给药途径、临床适应症和通路联繫起来的详细细分见解，有助于制定研发重点和商业化策略。

了解市场区隔趋势对于确定研发重点、通路策略和临床定位至关重要。在药物类别中，制酸剂在症状治疗中发挥基础作用，其活性成分各不相同，例如氢氧化铝、碳酸钙、氢氧化镁和碳酸氢钠。每种抗酸剂的耐受性、起效时间和给药途径各不相同，这影响了它们作为处方药和非处方药的定位。止泻药，包括次水杨酸铋和洛哌丁胺等化合物，继续满足急性治疗需求，并在间歇性治疗策略中发挥关键作用。解痉药，包括二环己胺和莨菪碱等药物，用于治疗功能障碍，通常与饮食和行为疗法联合用于多方面治疗方法中。泻药和质子帮浦阻断剂作为补充治疗选择，需要针对安全性、长期使用效果和患者依从性进行差异化讯息。

美洲、欧洲、中东和非洲以及亚太地区的区域趋势和独特的医疗保健生态系统正在推动独特的监管、製造和商业策略。

区域趋势差异显着，直接影响监管策略、供应链结构和商业性实施。在美洲，循证报销和支付方主导的成本控制备受重视，并由此塑造了产品定位。先进的诊断技术在门诊和住院环境中都为展现产品价值提供了重要机会。研究、临床试验基础设施和成熟的分销网络促进了差异化治疗方法的快速商业化，而政策变化和对定价的严格审查则要求构建清晰的卫生经济学论点。

不同的竞争原型、策略联盟和能力主导的差异化如何塑造消化器官系统疗法的企业策略和商业性成果。

消化器官系统药物市场的竞争格局呈现出多元化的特点，既有老牌製药公司，也有灵活敏捷的专业生物技术公司、非专利药生产商和契约製造组织（CMO）。老牌品牌药生产商凭藉丰富的临床数据、与处方医生建立的稳固关係以及整合的销售团队来维持其市场地位，而专业生物技术公司则透过探索新的作用机制和特定适应症来脱颖而出。学名药和商品化产品在市场准入和销售量方面仍然占据重要地位，其价格压力影响着毛利率策略和产品生命週期延长策略。

为产业领导者提供切实可行的策略重点和营运干预措施，以增强韧性、加速创新并展现可持续的治疗价值。

产业领导者应优先采取一系列策略行动，以因应科学的复杂性、供应链的波动性和支付者的需求。首先，应投资于供应链多元化和韧性，具体措施包括发展二级供应商、加强与契约製造製造商的关係以及评估区域製造地，以降低关税和物流风险。将情境规划融入采购和供应策略，可以降低政策突变的风险，并保障病人获得医疗服务。

采用严谨的混合方法研究方法，结合专家的初步访谈、全面的二次分析、检验和品质保证，以检验实务见解。

本研究途径结合了结构化的专家访谈、对临床、监管和商业文献的详细二次分析以及系统性的整合，从而确保了研究结果的可靠性。主要研究包括对临床医生、供应链专家、监管人员和销售主管的定性访谈，旨在捕捉治疗方法采纳、处方集趋势和营运限制等方面的细微观点。基于这些第一手信息，研究人员对临床实践模式和商业策略进行了解读，并与同行评审文献和监管指导文件进行了交叉比对。

整合临床、商业性和营运方面的挑战，以确定胃肠道治疗领域持续成功的核心优先事项。

总之，消化器官系统疗法的市场格局正受到科学创新、变革性医疗服务模式以及贸易政策和支付方审查等外部压力的重塑。新治疗方法、以微生物组为中心的研究以及数位健康能力的相互作用，既为研发团队和商业团队带来了机会，也带来了挑战。同时，供应链韧性和关税考量已成为营运规划中不可或缺的要素，影响采购决策和定价策略。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：消化器官系统市场：依药物类别划分

  • 制酸剂
    • 氢氧化铝
    • 碳酸钙
    • 氢氧化镁
    • 碳酸氢钠
  • 止泻药
    • 次水杨酸铋
    • 洛哌丁胺
  • 解痉药
    • 二环胺
    • 莨菪碱
  • 泻药
  • 质子帮浦阻断剂
    • 奥美拉唑
    • Esomeprazole
    • 兰索拉唑
    • Rabeprazole
  • 运动兴奋剂
    • 多巴胺拮抗剂
    • 血清素 5-HT4 受体促效剂
    • 大环内酯类运动兴奋剂
  • 止吐药
    • Ondansetron
    • 丙氯拉嗪

第九章：消化器官系统药物市场：依给药途径划分

  • 注射药物
    • 肌肉内部
    • 静脉
  • 口服
    • 胶囊
      • 硬壳
      • 软凝胶
    • 粉末
    • 药片
  • 直肠

第十章：以分子类型分類的消化器官系统药物市场

  • 低分子
  • 生物製药
  • 生物相似药
  • 胜肽
  • 酵素替代疗法
  • 重组蛋白
  • 生物疗法製剂

第十一章：以剂型分類的消化器官系统药物市场

  • 速释製剂
  • 缓释製剂
  • 肠溶製剂
  • 固定剂量组合药物
  • 液体

第十二章：消化器官系统药物市场：依适应症划分

  • 便秘
  • 胃食道逆流症
  • 腹泻
  • 大肠激躁症
  • 消化性溃疡
  • 发炎性肠道疾病
    • 克隆氏症
    • 溃疡性大肠炎
  • 胃轻瘫

第十三章：消化器官系统药物市场：依最终用户划分

  • 诊所
    • 胃肠病诊所
    • 一般诊所
  • 家庭医疗保健
  • 医院

第十四章：消化器官系统药物市场：依分销管道划分

  • 离线
    • 医院药房
    • 零售药房
    • 专科药房
  • 网路药房

第十五章：消化器官系统药物市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章：消化器官系统药物市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章：消化器官系统药物市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章：美国消化器官系统药物市场

第十九章：中国消化器官系统药物市场

第20章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb
  • Cipla Limited
  • Cosmo Pharmaceuticals NV
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Ferring International Center SA
  • GlaxoSmithKline plc
  • Ironwood Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Reckitt Benckiser Group plc
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-434CCDA051D0

The Gastrointestinal Drugs Market was valued at USD 62.23 billion in 2025 and is projected to grow to USD 65.45 billion in 2026, with a CAGR of 5.45%, reaching USD 90.26 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 62.23 billion
Estimated Year [2026] USD 65.45 billion
Forecast Year [2032] USD 90.26 billion
CAGR (%) 5.45%

A strategic orientation to the evolving gastrointestinal therapeutic ecosystem that outlines clinical drivers, care delivery shifts, regulatory inflections, and patient-centered innovation

The gastrointestinal therapeutics landscape is at an inflection point driven by converging clinical, demographic, and technological forces. Chronic gastrointestinal disorders and acute symptom management continue to shape product demand, while evolving standards of care and patient expectations pressure manufacturers to innovate across mechanism of action, formulation, and delivery. Newer therapeutic modalities, including targeted small molecules, biologic-supporting strategies, and microbiome-centered approaches, are redefining treatment paradigms and creating novel pathways for clinical differentiation.

Alongside therapeutic innovation, healthcare delivery transformation-characterized by greater outpatient care, telehealth adoption, and personalized medicine initiatives-has shifted how patients access and adhere to treatments. Regulatory environments are adapting to expedited pathways and real-world evidence requirements, prompting companies to rethink development plans and post-market evidence generation. Meanwhile, cost containment and payer scrutiny remain persistent constraints that require careful commercial planning and evidence-based value propositions.

Taken together, these dynamics demand an integrated approach that synthesizes clinical insight, patient-centric product design, and supply chain resilience. This introduction frames the principal forces shaping gastrointestinal drug development and commercialization, setting the stage for deeper analysis into transformative shifts, tariff implications, segmentation performance, regional nuances, and recommended actions for stakeholders seeking to sustain competitive advantage.

Pivotal scientific, regulatory, and commercial transformations reshaping gastrointestinal therapeutics through microbiome science, precision approaches, and digital-enabled care delivery

Recent years have produced transformative shifts that are redefining how gastrointestinal disorders are understood, treated, and managed. Scientific advances have expanded beyond symptomatic relief toward interventions that modify underlying pathophysiology, including targeted agents that influence acid secretion, gut motility, and mucosal inflammation. Equally important is the emergence of microbiome science as a potential therapeutic lever; interventions that modulate microbial communities and intestinal barrier function are moving from discovery into clinical experimentation, challenging conventional drug development pathways.

Concurrently, precision approaches are gaining traction, supported by biomarker development, diagnostic refinement, and risk stratification tools that enable more tailored therapy selection. Digital health innovations that monitor symptoms, adherence, and real-world outcomes are proving complementary to pharmacological interventions and are increasingly incorporated into development programs and post-market strategies. Formulation technology is also evolving, with controlled-release systems, softgel capsules, and alternative routes of administration improving tolerability and adherence.

From a commercial perspective, consolidation and partnerships between specialty biotech and traditional pharmaceutical companies are accelerating knowledge transfer and enabling faster scale-up of novel modalities. Regulatory frameworks and payer expectations continue to adapt, creating both opportunities for accelerated access and the requirement for robust value demonstration. These combined shifts signal a landscape where scientific novelty, patient-centric delivery, and adaptive commercial models determine who wins and who falls behind.

How changes in trade policy and tariff measures reshape supply chain choices, cost structures, sourcing strategies, and commercial positioning across gastrointestinal therapeutics

The introduction of tariffs and trade measures can materially alter cost structures, supply-chain design, and sourcing decisions for gastrointestinal drug manufacturers and distributors. Increased duties on imported active pharmaceutical ingredients or finished dosage forms create immediate input-cost pressures that compel companies to re-evaluate supplier relationships, contract terms, and inventory strategies. In response, organizations often pursue nearshoring of production, expand dual-sourcing strategies, or intensify engagement with contract development and manufacturing partners to preserve margins and continuity of supply.

Tariff-driven cost pressures also have downstream commercial implications. Payers and procurement entities may intensify price negotiations or seek alternative therapeutics with favorable cost profiles, which in turn influences portfolio prioritization and lifecycle management decisions. Companies that proactively model tariff scenarios and embed contingency plans into procurement and pricing playbooks are better positioned to mitigate margin erosion. These measures include longer-term supply agreements, hedging strategies for raw material purchases, and investments in domestic manufacturing capacity where economically justified.

Regulatory compliance and customs complexity increase administrative burden, requiring closer coordination between regulatory, supply chain, and commercial teams. As a result, cross-functional planning becomes a competitive necessity rather than an operational nicety. Firms that combine agile sourcing, transparent supplier audits, and robust demand forecasting will navigate tariff volatility more successfully while maintaining patient access and service levels.

Deep segmentation insight linking therapeutic classes, delivery routes, clinical indications, and distribution pathways to inform R&D focus and commercialization strategies

Understanding segmentation dynamics is essential to prioritize R&D focus, channel strategies, and clinical positioning. Within drug class, antacids play a foundational role in symptomatic management and are differentiated by active agents such as aluminum hydroxide, calcium carbonate, magnesium hydroxide, and sodium bicarbonate, each with distinct tolerability, onset-of-action, and dosing profiles that inform formulary placement and over-the-counter positioning. Antidiarrheals, including compounds such as bismuth subsalicylate and loperamide, continue to serve acute care needs and remain important for episodic treatment strategies. Antispasmodics encompassing agents like dicyclomine and hyoscyamine address functional disorders and are frequently considered within multi-modal treatment regimens alongside dietary and behavioral interventions. Laxatives and proton pump inhibitors complete the therapeutic mix and require differentiated messaging around safety, chronic use implications, and patient adherence initiatives.

Route of administration distinctions influence clinical applicability and patient preference. Injectable forms, subdivided into intramuscular and intravenous modalities, are essential in acute care settings and hospital protocols, while oral administration, which spans capsules, powders, and tablets, remains the dominant outpatient delivery mode. Capsules themselves split into hard shell and soft gel formats, with soft gels often chosen for improved swallowing and bioavailability for certain actives. Topical approaches-delivered as creams, gels, or patches-offer localized symptom control and an alternative pathway for certain adjunctive treatments.

Indication-focused segmentation shapes clinical development and marketing priorities, with conditions such as constipation, diarrhea, gastroesophageal reflux disease, irritable bowel syndrome, and peptic ulcer disease each presenting unique efficacy, safety, and adherence challenges. Distribution channels alter access dynamics; brick-and-mortar pharmacies including hospital, retail, and specialty pharmacies remain critical for clinical settings while online pharmacies expand reach for chronic therapy and OTC sales. End users such as clinics-both gastroenterology and general practice-home healthcare environments, and hospitals require tailored engagement models, with clinics often influencing prescribing behavior and hospitals dictating inpatient formularies and acute care protocols.

Regional dynamics and differentiated healthcare ecosystems across the Americas, Europe Middle East & Africa, and Asia-Pacific that drive distinct regulatory, manufacturing, and commercial strategies

Regional dynamics vary significantly and directly influence regulatory strategy, supply chain configuration, and commercial execution. In the Americas, a strong emphasis on evidence-based reimbursement and payer-driven cost containment shapes product positioning, with significant opportunities tied to advanced diagnostics and value demonstration in both outpatient and hospital settings. Research, clinical trial infrastructure, and established distribution networks facilitate faster commercialization for differentiated therapies, while policy shifts and pricing scrutiny necessitate clear health-economic narratives.

Europe, the Middle East & Africa presents a mosaic of regulatory approaches and market maturity levels. Western European markets often demand comprehensive clinical and economic evidence and operate within sophisticated reimbursement frameworks, whereas emerging markets in the region may prioritize affordability and supply chain reliability. Regulatory harmonization efforts and regional procurement mechanisms can influence launch sequencing and pricing strategies. Manufacturers must balance portfolio access across heterogeneous healthcare systems by adapting pricing, localization of manufacturing, and partnerships with regional distributors.

Asia-Pacific markets are characterized by rapid growth in healthcare spending, expanding access, and diverse adoption patterns of innovative therapies. Manufacturing hubs and contract development and manufacturing organizations provide opportunities for cost-efficient production, while regulatory modernization in several countries accelerates approval pathways for novel agents. Patient populations with differing epidemiology and health-seeking behaviors require nuanced clinical and commercial strategies to optimize market entry and scale.

How diverse competitive archetypes, strategic alliances, and capability-led differentiation are shaping company strategies and commercial outcomes in gastrointestinal therapeutics

Competitive dynamics in gastrointestinal therapeutics are defined by a mix of legacy pharmaceutical firms, nimble specialty biotechs, generic manufacturers, and contract manufacturing organizations. Incumbent brand manufacturers often leverage extensive clinical data, established prescriber relationships, and integrated commercial teams to defend market positions, while specialized biotech firms pursue novel mechanisms and niche indications to create differentiation. Generics and commoditized products remain important for access and volume, exerting pricing pressure that shapes gross margin strategies and lifecycle extension tactics.

Strategic partnerships, licensing agreements, and technology collaborations are common as companies seek to combine capabilities in drug discovery, formulation technology, and digital health. Contract development and manufacturing partners play a pivotal role in enabling rapid scale-up and hedging supply risk, particularly for companies transitioning from early clinical proof-of-concept to commercial manufacturing. Business models that integrate real-world evidence platforms, patient support services, and digital adherence tools can strengthen therapeutic value propositions and support payer negotiations.

Successful companies increasingly adopt a portfolio approach that balances short-term revenue from established products with longer-term investment in innovative modalities. Emphasis on regulatory strategy, health economics, and targeted commercialization plans separates leaders who secure premium positioning from those who compete primarily on price.

Practical strategic priorities and operational interventions for industry leaders to strengthen resilience, accelerate innovation, and demonstrate sustained therapeutic value

Industry leaders should prioritize a set of strategic actions to navigate scientific complexity, supply-chain volatility, and payer demands. First, invest in supply chain diversification and resilience by developing secondary sourcing, strengthening relationships with contract manufacturers, and evaluating regional manufacturing footprints to mitigate tariff and logistics risk. Embedding scenario planning into procurement and supply strategies reduces exposure to abrupt policy changes and preserves patient access.

Second, accelerate capability building in microbiome research, biomarker development, and formulation science to capture emerging therapeutic opportunities. Supporting translational research and adaptive clinical designs will shorten development timelines and improve the likelihood of clinical differentiation. Third, integrate digital health and real-world evidence platforms into development and commercialization plans to support adherence, monitor outcomes, and substantiate value for payers and providers.

Fourth, tailor commercial models to distribution and end-user characteristics, aligning messaging and service offerings with the needs of hospitals, gastroenterology clinics, general practice clinics, and home healthcare providers. Finally, maintain active regulatory engagement and robust health-economic modeling to anticipate reimbursement trajectories and demonstrate value across diverse regional systems. These combined actions create a pragmatic roadmap for sustaining competitiveness and driving long-term growth.

A rigorous mixed-methods research approach combining expert primary engagement, comprehensive secondary analysis, triangulation, and quality assurance to validate actionable insights

The research approach combines structured primary engagement with domain experts, in-depth secondary analysis of clinical, regulatory, and commercial literature, and systematic synthesis to ensure credible insights. Primary research included qualitative interviews with clinicians, supply chain specialists, regulatory affairs leaders, and commercial executives to capture nuanced perspectives on therapeutic adoption, formulary dynamics, and operational constraints. These firsthand accounts informed interpretation of clinical practice patterns and commercial strategies, and were triangulated against peer-reviewed literature and regulatory guidance documents.

Secondary research encompassed analysis of scientific publications, clinical trial registries, regulatory notices, and public company disclosures to map innovation trends, safety considerations, and development pipelines. Synthesis involved cross-validating themes across data sources, identifying convergent trends, and highlighting areas of discrepancy that warrant further investigation. Limitations include variance in public reporting across regions and the evolving nature of clinical evidence for novel modalities. To mitigate these constraints, findings emphasize robust patterns and practitioner-validated insights rather than speculative projections.

Quality assurance comprised peer review by therapeutic area experts, methodological checks on source credibility, and iterative refinement of conclusions based on stakeholder feedback. This layered methodology supports a reliable foundation for strategic decision-making while acknowledging the dynamic context of gastrointestinal therapeutics.

Synthesis of clinical, commercial, and operational imperatives that identify the core priorities for sustained success in gastrointestinal therapeutics moving forward

In conclusion, the gastrointestinal therapeutics landscape is being reshaped by scientific innovation, shifts in care delivery, and external pressures such as trade policy and payer scrutiny. The interplay of new therapeutic modalities, microbiome-focused research, and digital health capabilities creates both opportunity and complexity for developers and commercial teams. At the same time, supply-chain resilience and tariff awareness have become essential components of operational planning, influencing sourcing decisions and pricing strategies.

Segmentation clarity-across drug classes, routes of administration, clinical indications, distribution channels, and end users-remains critical to prioritize investment and craft targeted value propositions. Regional heterogeneity further necessitates adaptable regulatory and commercialization plans that reflect distinct payer expectations and healthcare infrastructure. Companies that combine scientific rigor with pragmatic supply-chain planning, integrated digital strategies, and strong payer engagement will be best positioned to deliver differentiated therapies that meet clinical needs while achieving sustainable commercial returns.

The path forward favors organizations that embrace cross-functional collaboration, invest in translational science, and maintain agility in the face of policy and market shifts. By aligning development priorities with real-world care delivery demands and operational resilience, stakeholders can capture emerging opportunities while safeguarding patient access and therapeutic continuity.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gastrointestinal Drugs Market, by Drug Class

  • 8.1. Antacids
    • 8.1.1. Aluminum Hydroxide
    • 8.1.2. Calcium Carbonate
    • 8.1.3. Magnesium Hydroxide
    • 8.1.4. Sodium Bicarbonate
  • 8.2. Antidiarrheals
    • 8.2.1. Bismuth Subsalicylate
    • 8.2.2. Loperamide
  • 8.3. Antispasmodics
    • 8.3.1. Dicyclomine
    • 8.3.2. Hyoscyamine
  • 8.4. Laxatives
  • 8.5. Proton Pump Inhibitors
    • 8.5.1. Omeprazole
    • 8.5.2. Esomeprazole
    • 8.5.3. Lansoprazole
    • 8.5.4. Rabeprazole
  • 8.6. Prokinetics
    • 8.6.1. Dopamine Antagonists
    • 8.6.2. Serotonin 5-HT4 Agonists
    • 8.6.3. Macrolide Prokinetics
  • 8.7. Antiemetics
    • 8.7.1. Ondansetron
    • 8.7.2. Prochlorperazine

9. Gastrointestinal Drugs Market, by Route Of Administration

  • 9.1. Injectable
    • 9.1.1. Intramuscular
    • 9.1.2. Intravenous
  • 9.2. Oral
    • 9.2.1. Capsules
      • 9.2.1.1. Hard Shell
      • 9.2.1.2. Soft Gel
    • 9.2.2. Powders
    • 9.2.3. Tablets
  • 9.3. Rectal

10. Gastrointestinal Drugs Market, by Molecule Type

  • 10.1. Small Molecule
  • 10.2. Biologic
  • 10.3. Biosimilar
  • 10.4. Peptide
  • 10.5. Enzyme Replacement
  • 10.6. Recombinant Protein
  • 10.7. Live Biotherapeutic

11. Gastrointestinal Drugs Market, by Formulation Type

  • 11.1. Immediate Release
  • 11.2. Extended Release
  • 11.3. Enteric Coated
  • 11.4. Fixed Dose Combination
  • 11.5. Liquid Formulation

12. Gastrointestinal Drugs Market, by Indication

  • 12.1. Constipation
  • 12.2. Gastroesophageal Reflux Disease
  • 12.3. Diarrhea
  • 12.4. Irritable Bowel Syndrome
  • 12.5. Peptic Ulcer Disease
  • 12.6. Inflammatory Bowel Disease
    • 12.6.1. Crohn's Disease
    • 12.6.2. Ulcerative Colitis
  • 12.7. Gastroparesis

13. Gastrointestinal Drugs Market, by End User

  • 13.1. Clinics
    • 13.1.1. Gastroenterology Clinics
    • 13.1.2. General Practice Clinics
  • 13.2. Home Healthcare
  • 13.3. Hospitals

14. Gastrointestinal Drugs Market, by Distribution Channel

  • 14.1. Offline
    • 14.1.1. Hospital Pharmacies
    • 14.1.2. Retail Pharmacies
    • 14.1.3. Specialty Pharmacies
  • 14.2. Online Pharmacies

15. Gastrointestinal Drugs Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Gastrointestinal Drugs Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Gastrointestinal Drugs Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Gastrointestinal Drugs Market

19. China Gastrointestinal Drugs Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. AbbVie Inc.
  • 20.6. Amgen Inc.
  • 20.7. AstraZeneca PLC
  • 20.8. Bausch Health Companies Inc.
  • 20.9. Bayer AG
  • 20.10. Boehringer Ingelheim International GmbH
  • 20.11. Bristol-Myers Squibb
  • 20.12. Cipla Limited
  • 20.13. Cosmo Pharmaceuticals N.V.
  • 20.14. Dr. Reddy's Laboratories Ltd.
  • 20.15. Eli Lilly and Company
  • 20.16. F. Hoffmann-La Roche Ltd
  • 20.17. Ferring International Center S.A.
  • 20.18. GlaxoSmithKline plc
  • 20.19. Ironwood Pharmaceuticals, Inc.
  • 20.20. Johnson & Johnson Services, Inc.
  • 20.21. Merck & Co., Inc.
  • 20.22. Novartis AG
  • 20.23. Otsuka Pharmaceutical Co., Ltd.
  • 20.24. Pfizer Inc.
  • 20.25. Reckitt Benckiser Group plc
  • 20.26. Sanofi S.A.
  • 20.27. Takeda Pharmaceutical Company Limited
  • 20.28. Teva Pharmaceutical Industries Ltd.
  • 20.29. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GASTROINTESTINAL DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GASTROINTESTINAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY FORMULATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES GASTROINTESTINAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA GASTROINTESTINAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTACIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTACIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTACIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTACIDS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ALUMINUM HYDROXIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ALUMINUM HYDROXIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ALUMINUM HYDROXIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY CALCIUM CARBONATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY CALCIUM CARBONATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY CALCIUM CARBONATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY MAGNESIUM HYDROXIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY MAGNESIUM HYDROXIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY MAGNESIUM HYDROXIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY SODIUM BICARBONATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY SODIUM BICARBONATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY SODIUM BICARBONATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIDIARRHEALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIDIARRHEALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIDIARRHEALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIDIARRHEALS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY BISMUTH SUBSALICYLATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY BISMUTH SUBSALICYLATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY BISMUTH SUBSALICYLATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY LOPERAMIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY LOPERAMIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY LOPERAMIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTISPASMODICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTISPASMODICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTISPASMODICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTISPASMODICS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DICYCLOMINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DICYCLOMINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DICYCLOMINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY HYOSCYAMINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY HYOSCYAMINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY HYOSCYAMINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY LAXATIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY LAXATIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY LAXATIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY OMEPRAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY OMEPRAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY OMEPRAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ESOMEPRAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ESOMEPRAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ESOMEPRAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY LANSOPRAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY LANSOPRAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY LANSOPRAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY RABEPRAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY RABEPRAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY RABEPRAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY PROKINETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY PROKINETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY PROKINETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY PROKINETICS, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY SEROTONIN 5-HT4 AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY SEROTONIN 5-HT4 AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY SEROTONIN 5-HT4 AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY MACROLIDE PROKINETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY MACROLIDE PROKINETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY MACROLIDE PROKINETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIEMETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIEMETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIEMETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ONDANSETRON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ONDANSETRON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ONDANSETRON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY PROCHLORPERAZINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY PROCHLORPERAZINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY PROCHLORPERAZINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY HARD SHELL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY HARD SHELL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY HARD SHELL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY SOFT GEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY SOFT GEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY SOFT GEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY POWDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY POWDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY RECTAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY RECTAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY RECTAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY BIOLOGIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY BIOLOGIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY BIOLOGIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY BIOSIMILAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY BIOSIMILAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY BIOSIMILAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY PEPTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY PEPTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY PEPTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ENZYME REPLACEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ENZYME REPLACEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ENZYME REPLACEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY RECOMBINANT PROTEIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY RECOMBINANT PROTEIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY RECOMBINANT PROTEIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY LIVE BIOTHERAPEUTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY LIVE BIOTHERAPEUTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY LIVE BIOTHERAPEUTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ENTERIC COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ENTERIC COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ENTERIC COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY LIQUID FORMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY LIQUID FORMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY LIQUID FORMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY CONSTIPATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY CONSTIPATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY CONSTIPATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DIARRHEA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DIARRHEA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DIARRHEA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY PEPTIC ULCER DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY PEPTIC ULCER DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY PEPTIC ULCER DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY CROHN'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY CROHN'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ULCERATIVE COLITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ULCERATIVE COLITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY GASTROPARESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY GASTROPARESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY GASTROPARESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY GASTROENTEROLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY GASTROENTEROLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY GASTROENTEROLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 217. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 218. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 219. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTACIDS, 2018-2032 (USD MILLION)
  • TABLE 220. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIDIARRHEALS, 2018-2032 (USD MILLION)
  • TABLE 221. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTISPASMODICS, 2018-2032 (USD MILLION)
  • TABLE 222. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 223. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY PROKINETICS, 2018-2032 (USD MILLION)
  • TABLE 224. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2032 (USD MILLION)
  • TABLE 225. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 226. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 227. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 228. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 229. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 232. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 233. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 235. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTACIDS, 2018-2032 (USD MILLION)
  • TABLE 240. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIDIARRHEALS, 2018-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTISPASMODICS, 2018-2032 (USD MILLION)
  • TABLE 242. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY PROKINETICS, 2018-2032 (USD MILLION)
  • TABLE 244. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 246. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 248. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 252. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 256. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 258. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTACIDS, 2018-2032 (USD MILLION)
  • TABLE 260. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIDIARRHEALS, 2018-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTISPASMODICS, 2018-2032 (USD MILLION)
  • TABLE 262. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY PROKINETICS, 2018-2032 (USD MILLION)
  • TABLE 264. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 266. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 268. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 272. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 274. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 276. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTACIDS, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIDIARRHEALS, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTISPASMODICS, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY PROKINETICS, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 297. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 299. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTACIDS, 2018-2032 (USD MILLION)
  • TABLE 300. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIDIARRHEALS, 2018-2032 (USD MILLION)
  • TABLE 301. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTISPASMODICS, 2018-2032 (USD MILLION)
  • TABLE 302. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 303. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY PROKINETICS, 2018-2032 (USD MILLION)
  • TABLE 304. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 306. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 307. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 308. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 309. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILL